Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1 antibody with clinical activity in various tumor t...

Full description

Bibliographic Details
Main Authors: Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, Yoshitaka Inaba, Yasunari Sakamoto, Masayuki Kurosaki, Yoshiko Umeyama, Yoichi Kamei, Junichiro Yoshimitsu, Yosuke Fujii, Mana Aizawa, Paul B. Robbins, Junji Furuse
Format: Article
Language:English
Published: Karger Publishers 2021-04-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
immune checkpoint inhibitor
vascular endothelial growth factor receptor tyrosine kinase inhibitor
avelumab
axitinib
Online Access:https://www.karger.com/Article/FullText/514420

Internet

https://www.karger.com/Article/FullText/514420

Similar Items